Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




LAMP Malaria Test Detects Less-Diagnosed Species

By LabMedica International staff writers
Posted on 16 May 2019
A new loop-mediated isothermal amplification (LAMP) molecular assay has been developed that can detect Plasmodium vivax, a species of the parasite that causes malaria.

Almost all molecular tests currently available detect P. More...
falciparum, in part because it causes the highest mortality of the different species. However, P. vivax is actually more widespread, with more than 2.5 billion people at risk of infection.

The new LAMP assay was evaluated recently in Colombia using a protocol of consecutive testing, a pan-plasmodium LAMP test followed by the P. vivax test, with polymerase chain reaction (PCR)-based testing as the comparator. In all, 365 fingerpick blood samples from patients with fever were evaluated, and the P. vivax test showed a sensitivity of approximately 94% and a specificity of 92%. Importantly, the test also has a low limit of detection of around one to two parasites per microliter of patient sample.

The LAMP assay was developed by Eiken Chemical (Tokyo, Japan) with the collaboration of The Foundation for Innovative New Diagnostics (FIND, Geneva, Switzerland) who coordinated laboratory testing in collaboration with the Hospital for Tropical Diseases (London, UK). FIND has negotiated pricing for the Loopamp tests and HumaTurb system, with a kit of 96 P. vivax tests costing EUR 499.20 (USD 560) and the HumaTurb costing EUR 15,900. There is also a solution for lower-throughput settings called HumaLoop that is a lower cost.

Xavier C. Ding, PhD, the team leader for malaria diagnostics at FIND, said, “It's only recently that there is a recognition that if we are ever to eliminate malaria, we also need some vivax-specific tests, because that species has its own biological specificities and is much more challenging to eliminate that falciparum.” This is because, unlike P. falciparum, P. vivax can lie dormant in the liver of an infected person in a stage called a hypnozoite, and a person with hypnozoites is then prone to relapsing malarial disease. Dr. Ding added, “There is big hope that this will make it easier and more accessible to get treatment for liver-stage parasites, but that also means you also need good diagnostic tools to identify those people who have vivax.”

Related Links:
Eiken Chemical
The Foundation for Innovative New Diagnostics
Hospital for Tropical Diseases


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.